Interventional device developer Abbott Laboratories of Abbott Park, IL, plans to begin enrolling patients in a new clinical trial to compare carotid artery stenting to carotid artery surgery.
Dubbed ACT I, the study will be a multicenter randomized trial that will examine both therapeutic approaches in asymptomatic patients who normally would be referred to surgery. These patients have not displayed stroke symptoms, but have been determined to be at risk due to other criteria.
Abbott said the trial is a step toward bringing the benefits of minimally invasive procedures to all patients at risk of stroke due to carotid artery disease. The study will use Abbott's Xact stent, which is under Food and Drug Administration review for carotid artery stenting for patients who require immediate intervention to prevent a stroke, but for whom surgery presents too high a risk. The ACT I study could potentially demonstrate that carotid artery stenting is appropriate for a larger patient population: those who are at standard risk for surgery.
By AuntMinnie.com staff writers
January 20, 2005
Related Reading
Abbott plans drug-eluting stent trial, September 28, 2004
Abbott starts ZoMaxx stent trial, September 17, 2004
Abbott debuts StarClose, May 26, 2004
Abbott launches Perclose ProGlide, May 13, 2004
Abbott Labs launches endovascular unit, January 28, 2004
Copyright © 2005 AuntMinnie.com
